Addex Therapeutics Ltd
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson's disease levodopa-in… Read more
Addex Therapeutics Ltd (ADXN) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.089x
Based on the latest financial reports, Addex Therapeutics Ltd (ADXN) has a cash flow conversion efficiency ratio of -0.089x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-533.20K) by net assets ($5.96 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Addex Therapeutics Ltd - Cash Flow Conversion Efficiency Trend (2006–2024)
This chart illustrates how Addex Therapeutics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Addex Therapeutics Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Addex Therapeutics Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SeaStar Medical Holding Corporation
NASDAQ:ICU
|
-0.335x |
|
Shreyans Industries Limited
NSE:SHREYANIND
|
0.039x |
|
VVT Med Inc.
V:VVTM
|
3.168x |
|
BMC
ST:BMC
|
0.337x |
|
Tong Herr Resources Bhd
KLSE:5010
|
0.061x |
|
EarthRenew Inc
PINK:VVIVF
|
-0.023x |
|
Kalyani Forge Limited
NSE:KALYANIFRG
|
-0.027x |
|
TRANSILVANIA BROKER DE ASIGURARE
RO:TBK
|
N/A |
Annual Cash Flow Conversion Efficiency for Addex Therapeutics Ltd (2006–2024)
The table below shows the annual cash flow conversion efficiency of Addex Therapeutics Ltd from 2006 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $9.68 Million | $-5.37 Million | -0.555x | +92.04% |
| 2023-12-31 | $1.15 Million | $-7.99 Million | -6.977x | -108.55% |
| 2022-12-31 | $4.91 Million | $-16.44 Million | -3.346x | -285.22% |
| 2021-12-31 | $16.93 Million | $-14.71 Million | -0.869x | -4.18% |
| 2020-12-31 | $14.61 Million | $-12.18 Million | -0.834x | -124.41% |
| 2019-12-31 | $25.52 Million | $-9.48 Million | -0.372x | -932.20% |
| 2018-12-31 | $39.24 Million | $1.75 Million | 0.045x | +102.81% |
| 2017-12-31 | $1.34 Million | $-2.13 Million | -1.590x | +87.10% |
| 2016-12-31 | $218.59K | $-2.69 Million | -12.326x | -680.44% |
| 2015-12-31 | $1.66 Million | $-2.63 Million | -1.579x | -105.86% |
| 2014-12-31 | $2.35 Million | $-1.80 Million | -0.767x | +85.28% |
| 2013-12-31 | $3.03 Million | $-15.78 Million | -5.214x | -188.38% |
| 2012-12-31 | $16.29 Million | $-29.45 Million | -1.808x | -130.40% |
| 2011-12-31 | $33.84 Million | $-26.55 Million | -0.785x | -61.27% |
| 2010-12-31 | $64.41 Million | $-31.34 Million | -0.487x | +4.14% |
| 2009-12-31 | $77.58 Million | $-39.38 Million | -0.508x | -239.45% |
| 2008-12-31 | $118.99 Million | $-17.79 Million | -0.150x | +36.53% |
| 2007-12-31 | $140.11 Million | $-33.00 Million | -0.236x | +49.08% |
| 2006-12-31 | $42.28 Million | $-19.56 Million | -0.463x | -- |